USD
GBP 
CNY 
EUR 
INR 
JPY 
MYR 
ZAR 
KRW 
THB 
U.S. Diabetes Pipeline Outlook
22-Nov-2006
North America
Market Research
N097-01-00-00-00
HC02005-NA-MR_07295
This research service covers the pharmaceutical industry development pipeline for diabetes mellitus in the United States, with 2005 as the base year. Included are both the products projected to enter the market by the end of the forecast coverage period in 2012, as well as products entering the market in 2005 that correspond to the in-depth discussion drug classes. The focus of this piece is on pipeline technology developments and has greater focus on: GLP-1 Agonists, DPP-IV Inhibitors; PPAR Modulators; and Pulmonary Insulin. Also discussed are pipeline developments in other areas of oral antidiabetic drugs, injectables, and insulins other than pulmonary. Product Analysis charts are included for those products in Phase III clinical trials.
Executive Summary
- Introduction
Research Scope and Methodology
- Scope and Segmentation
- Research Methodology
Diabetes Overview
- Introduction
- Types of Diabetes
- Prevalence
- Incidence
- Current Treatment
Pipeline Competitive Analysis
- Introduction
- Key Pipeline Companies
- Areas of Opportunity
Introduction
GLP-1 Agonists Pipeline Analysis
Introduction
Pulmonary Insulin Analysis
Introduction
DPP-IV Pipeline Analysis
Introduction
PPAR Pipeline Analysis
Introduction
Pipeline Overviews
Decision Support Databases
Speak directly with our analytics experts for tailored recommendations.
Recent related Healthcare research
16 Oct 2026 | Global | Market Research
Public Sector Healthcare Cloud Market, North America and Europe, 2026
Public healthcare organizations across North America and Europe are using cloud technologies to support modernization efforts that extend beyond infrastructure replacement. Cloud is increasingly being adopted to improve interoperability, enable secure data sharing, support analytics and AI initiativ...
16 Oct 2026 | Global | Technology Research
Innovations and Growth Opportunities in Precision Therapeutics, AI-Enabled Discovery and Bioengineering, Regenerative Medicine, and Next-Generation Vaccine Platforms
This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations transforming precision therapeutics, regenerative medicine, AI-enabled discovery, laboratory automation, targeted delivery, vaccines, and biomanufactu...
15 Oct 2026 | Global | Frost Radar
Frost Radar™: US and European Mammalian Contract Development and Manufacturing Organizations, 2026
The US and European mammalian contract development and manufacturing organization (CDMO) market is entering a new phase of strategic evolution, driven by accelerating biologics outsourcing, increasing molecule complexity, and growing demand for resilient, end-to-end manufacturing partnerships. As mo...
08 Oct 2026 | Global | Frost Radar
Frost Radar: Endoscopy Device Technology Ecosystem, 2026
The endoscopy device market is advancing toward higher-quality visualization and improved clinical decision-making, with innovation across 4K ultrahigh-definition display systems, image-enhanced endoscopy, and computer-aided detection systems. Advanced visualization is evolving through improvements ...
07 Oct 2026 | Global | Technology Research
Growth Opportunities in Image-Guided Cancer Ablation Systems
Image-guided cancer ablation systems are minimally invasive medical technologies that use real-time imaging to accurately guide the placement of an ablation device into a tumor, enabling localized destruction of cancerous tissue while minimizing damage to surrounding healthy structures.The increasin...
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.